Zura Bio (ZURA) Stock Overview
A clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ZURA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Zura Bio Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.67 |
| 52 Week High | US$4.85 |
| 52 Week Low | US$0.97 |
| Beta | 0.24 |
| 1 Month Change | -15.44% |
| 3 Month Change | 158.45% |
| 1 Year Change | -19.87% |
| 3 Year Change | -63.77% |
| 5 Year Change | n/a |
| Change since IPO | -62.16% |
Recent News & Updates
Shareholder Returns
| ZURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.4% | -0.6% | -2.0% |
| 1Y | -19.9% | -1.1% | 12.1% |
Return vs Industry: ZURA underperformed the US Biotechs industry which returned 0.3% over the past year.
Return vs Market: ZURA underperformed the US Market which returned 12.3% over the past year.
Price Volatility
| ZURA volatility | |
|---|---|
| ZURA Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZURA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ZURA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 30 | Kim Davis | zurabio.com |
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies.
Zura Bio Limited Fundamentals Summary
| ZURA fundamental statistics | |
|---|---|
| Market cap | US$226.26m |
| Earnings (TTM) | -US$65.42m |
| Revenue (TTM) | n/a |
Is ZURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$65.43m |
| Earnings | -US$65.42m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 13:24 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zura Bio Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Matthew Barcus | Chardan Capital Markets, LLC |
| Daniil Gataulin | Chardan Capital Markets, LLC |